Optimizing Antimicrobial Use in Maintenance Dialysis Units (OPTIMUS)
优化维持性透析装置中的抗菌药物使用 (OPTIMUS)
基本信息
- 批准号:10436161
- 负责人:
- 金额:$ 2.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Rates of multidrug-resistant organisms (MDRO) are among the highest in persons requiring maintenance
hemodialysis (MHD). Antimicrobial exposure is the main risk factor for the emergence and spread of MDRO. Up
to 30% of antimicrobials administered in out-patient dialysis facilities are not indicated. Decreasing inappropriate,
unnecessary or suboptimal antimicrobial use in dialysis facilities is therefore crucial. We recently published a
decision analytic model on the clinical and economic consequences of implementing antimicrobial stewardship
programs (ASP) in out-patient dialysis facilities nation-wide. The model predicted a 4.8% reduction in infections
caused by MDRO and Clostridium difficile; a 4.6% reduction in infection-related deaths and a 5.0% reduction in
costs. In 2017, the PI completed an AHRQ-funded study of an ASP in out-patient dialysis facilities. The program,
which focused on educational and behavioral strategies, resulted in a reduction in antimicrobial use (P=0.02).
Although successful, three barriers to even greater effective prescribing were identified. First, our initial ASP
method could not fully identify inappropriate doses, administered after the empiric doses, in a timely manner.
Thus, opportunities for improving prescribing were missed. Second, approximately 55% of doses prescribed
were from orders received from the transferring hospital upon hospital discharge. Data pertaining to the
indications for and choice of antimicrobial therapy were minimal and thereby limited the number of opportunities
to improve antimicrobial prescribing. Third, engagement from unit medical directors was minimal. Lack of
leadership support likely prevented the ASP to be more effective. With this foundation and leveraging a research
infrastructure established during our previous AHRQ grant, this proposal, entitled OPTIMUS (Optimizing
Antimicrobial Use In Maintenance Dialysis UnitS), will develop and implement an improved ASP. In addition to
the previous educational and behavioral components, specific tools and strategies to overcome the three barriers
mentioned above will be developed and implemented in this improved ASP. These tools include an antimicrobial
hospital transfer report and an evidence-based checklist for antimicrobial prescribing in the dialysis facilities. We
will enroll DaVita dialysis units and have already obtained leadership support. Our interdisciplinary team includes
investigators with expertise in ASP and implementation science, senior nephrologists with experience in quality
improvement initiatives and our CDC consultant, with expertise in MHD healthcare quality. An interrupted time
series design will be used in 8 intervention and 8 control units. Specific aims are:1] To develop and implement
an improved ASP in out-patient hemodialysis units, 2] To demonstrate the effectiveness of this ASP in reducing
antimicrobial use, and 3] To develop a dialysis setting specific-antimicrobial prescribing audit tool and
demonstrate improvement in the quality of antimicrobial prescribing patterns as a result of the ASP.
Demonstrating the efficacy of this ASP and generating tools to assist in optimizing antimicrobial prescribing will
provide an unmet and overdue need in the MHD population and will ultimately improve their health outcomes.
多重耐药菌(MDRO)的比率在需要维持的人中是最高的
血液透析(MHD)。抗菌药物暴露是MDRO出现和传播的主要危险因素。向上
在门诊透析设施使用的抗菌药中,有30%没有注明。减少不适当的,
因此,在透析设施中使用不必要或不理想的抗菌剂是至关重要的。我们最近发表了一篇
实施抗菌药物管理的临床和经济后果决策分析模型
在全国范围内的门诊透析设施的计划(ASP)。该模型预测感染人数将减少4.8%
由MDRO和艰难梭菌引起;与感染相关的死亡减少4.6%,
成本。2017年,PI完成了一项由AHRQ资助的关于门诊透析设施中的ASP的研究。该计划,
重点是教育和行为策略,导致抗菌药的使用减少(P=0.02)。
尽管取得了成功,但仍发现了三个障碍,以实现更有效的处方。首先,我们最初的ASP
方法不能完全识别不适当的剂量,在经验量之后及时给药。
因此,错过了改善处方的机会。第二,约55%的处方剂量
是出院时从转院医院接到的命令。与数据相关的数据
抗菌治疗的适应症和选择很少,因此限制了机会的数量
改进抗菌药物处方。第三,单位医务主任的参与度很低。缺乏
领导层的支持可能会阻止ASP变得更有效。在此基础上,利用一项研究
在我们上一次AHRQ拨款期间建立的基础设施,这项题为Optimus(优化)的建议
抗菌剂在维护透析单元中的使用),将开发和实施一种改进的ASP。除了……之外
克服三大障碍的教育和行为构成要素、具体工具和战略
上述内容将在这个改进的ASP中开发和实现。这些工具包括一种抗菌剂
医院转院报告和透析设施中抗菌药物处方的循证检查表。我们
将加入达维塔透析单元,并已获得领导支持。我们的跨学科团队包括
具有ASP和实施科学专业知识的研究人员,具有质量经验的资深肾病学家
改善计划和我们的疾控中心顾问,在MHD医疗质量方面拥有专业知识。中断的时间
8个干预单元和8个控制单元将采用系列化设计。具体目标是:1]制定和实施
一种改进的门诊血液透析室的ASP,2]论证这种ASP在减少
抗菌药物使用,以及3]开发透析环境专用抗菌药物处方审计工具和
展示由于ASP的结果,抗菌药物处方模式的质量有所改善。
演示此ASP的有效性,并生成工具以帮助优化抗菌药物处方
在MHD人群中提供未得到满足和早该满足的需求,并最终改善他们的健康状况。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERIKA M D'AGATA其他文献
ERIKA M D'AGATA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERIKA M D'AGATA', 18)}}的其他基金
The INFECTADO study: INFECTions Acquired by persons on maintenance hemoDialysis during hOspitalizations
INFECTADO 研究:住院期间接受维持性血液透析的人获得的感染
- 批准号:
10731626 - 财政年份:2023
- 资助金额:
$ 2.78万 - 项目类别:
Optimizing Antimicrobial Use in Maintenance Dialysis Units (OPTIMUS)
优化维持性透析装置中的抗菌药物使用 (OPTIMUS)
- 批准号:
10161826 - 财政年份:2020
- 资助金额:
$ 2.78万 - 项目类别:
Optimizing Antimicrobial Use in Maintenance Dialysis Units (OPTIMUS)
优化维持性透析装置中的抗菌药物使用 (OPTIMUS)
- 批准号:
10641882 - 财政年份:2020
- 资助金额:
$ 2.78万 - 项目类别:
Optimizing Antimicrobial Use in Maintenance Dialysis Units (OPTIMUS)
优化维持性透析装置中的抗菌药物使用 (OPTIMUS)
- 批准号:
10816199 - 财政年份:2020
- 资助金额:
$ 2.78万 - 项目类别:
COBRE Center for Antimicrobial Resistance and Therapeutic Discovery - Administrative Core
COBRE 抗菌素耐药性和治疗发现中心 - 行政核心
- 批准号:
10488622 - 财政年份:2018
- 资助金额:
$ 2.78万 - 项目类别:
COBRE Center for Antimicrobial Resistance and Therapeutic Discovery
COBRE 抗菌素耐药性和治疗发现中心
- 批准号:
10488596 - 财政年份:2018
- 资助金额:
$ 2.78万 - 项目类别:
Midcareer Investigator Award in Patient-Oriented Research
以患者为导向的研究中的职业生涯中期研究员奖
- 批准号:
9108690 - 财政年份:2016
- 资助金额:
$ 2.78万 - 项目类别:
Midcareer Investigator Award in Patient-Oriented Research
以患者为导向的研究中的职业生涯中期研究员奖
- 批准号:
9235244 - 财政年份:2016
- 资助金额:
$ 2.78万 - 项目类别:
A Pilot Study of an RCT to Improve Infection Management in Advanced Dementia
改善晚期痴呆症感染管理的随机对照试验试点研究
- 批准号:
8441316 - 财政年份:2013
- 资助金额:
$ 2.78万 - 项目类别:
A Pilot Study of an RCT to Improve Infection Management in Advanced Dementia
改善晚期痴呆症感染管理的随机对照试验试点研究
- 批准号:
8676621 - 财政年份:2013
- 资助金额:
$ 2.78万 - 项目类别:
相似海外基金
A pragmatic randomized trial to evaluate the effect of a peer-comparison feedback letter on antimicrobial use in hospital-based physicians
一项实用的随机试验,旨在评估同行比较反馈信对医院医生抗菌药物使用的影响
- 批准号:
483302 - 财政年份:2023
- 资助金额:
$ 2.78万 - 项目类别:
Operating Grants
A pragmatic randomized trial to evaluate the effect of a peer-comparison feedback letter on antimicrobial use in hospital-based physicians
一项实用的随机试验,旨在评估同行比较反馈信对医院医生抗菌药物使用的影响
- 批准号:
490409 - 财政年份:2023
- 资助金额:
$ 2.78万 - 项目类别:
Operating Grants
Developing and assessing the utility of a digital dashboard for surveillance of antimicrobial use in Nova Scotia
开发和评估用于监测新斯科舍省抗菌药物使用情况的数字仪表板的实用性
- 批准号:
478077 - 财政年份:2023
- 资助金额:
$ 2.78万 - 项目类别:
Operating Grants
Clinical epidemiological research on appropriate antimicrobial use in dentistry and oral surgery
牙科和口腔外科适当使用抗菌药物的临床流行病学研究
- 批准号:
23K16241 - 财政年份:2023
- 资助金额:
$ 2.78万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Reducing antimicrobial resistant bacteria with the use of cold atmospheric plasma: Mechanism of action and influence on mutation and horizontal gene t
使用冷大气等离子体减少抗菌药物耐药性细菌:作用机制以及对突变和水平基因t的影响
- 批准号:
2888329 - 财政年份:2023
- 资助金额:
$ 2.78万 - 项目类别:
Studentship
Convergent evolution of Enterobacteriaceae in epidemiological networks with high antimicrobial use
高抗菌药物使用流行病学网络中肠杆菌科的趋同进化
- 批准号:
BB/V009184/2 - 财政年份:2023
- 资助金额:
$ 2.78万 - 项目类别:
Research Grant
Advancing health risk Literacy about Antimicrobial Resistance through the use of Metaphors (ALARM): An international comparative study
通过使用隐喻提高健康风险素养(ALARM):一项国际比较研究
- 批准号:
ES/X001652/1 - 财政年份:2023
- 资助金额:
$ 2.78万 - 项目类别:
Research Grant
Genomics to inform antimicrobial use in livestock
基因组学为牲畜抗菌药物的使用提供信息
- 批准号:
RGPIN-2020-04447 - 财政年份:2022
- 资助金额:
$ 2.78万 - 项目类别:
Discovery Grants Program - Individual
Decreasing antimicrobial use through selective dry cow therapy: unintended consequences, and economic impact in Alberta dairy farms
通过选择性干奶牛疗法减少抗菌药物的使用:艾伯塔省奶牛场的意外后果和经济影响
- 批准号:
546794-2020 - 财政年份:2022
- 资助金额:
$ 2.78万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Doctoral
The use of dosing software with Bayesian forecasting to improve antimicrobial-plasma concentrations in the Intensive Care Unit
使用贝叶斯预测剂量软件来提高重症监护病房的抗菌血浆浓度
- 批准号:
nhmrc : 2002981 - 财政年份:2021
- 资助金额:
$ 2.78万 - 项目类别:
Postgraduate Scholarships














{{item.name}}会员




